Skip to main content
. 2015 Jan 22;86(1):100–107. doi: 10.3109/17453674.2015.1004149

Table 2.

Age-adjusted relative risk (RR) and absolute risk (AR), with 95% confidence intervals (95% CIs), of atypical femoral fracture associated with use of bisphosphonate in women and men 55 years of age or older, during the 3-year period 2008–2010

Bisphosphonate use No. of atypical fractures Crude incidence n/10,000 patient-years Age-adjusted RR (95% CI) Age-adjusted AR (95% CI)
Women
 Never use 30 0.08 Reference Reference
 Any type of bisphosphonate 130 5.0 55 (39–79) 0.0005 (0.0004–0.0006)
 Alendronate 117 5.9 63 (41–97) 0.0006 (0.0005–0.0007)
 Risedronate 15 5.4 35 (19–66) 0.0003 (0.0001–0.0006)
Men
 Never use 8 0.03 Reference Reference
 Any type of bisphosphonate 4 1.6 54 (15–192) 0.0002 (0.0000–0.0003)
Women compared to men a
 Men, users of bisphosphonate 4 1.6 Reference Reference
 Women, users of bisphosphonate 86 5.0 3.1 (1.1–8.4) 0.0003 (0.0001–0.0005)
 Men, non-users 8 0.030 Reference Reference
 Women, non-users 21 0.072 2.3 (1.0–5.3) < 0.000001
a

Based on data from 2009 and 2010.

HHS Vulnerability Disclosure